Quadrivalent human papillomavirus recombinant vaccine: the first vaccine for cervical cancers.

Simple item page
dc.contributor.authorSharma, Rashmien_US
dc.contributor.authorSharma, Chaman Lalen_US
dc.date.accessioned2007-04-14en_US
dc.date.accessioned2009-06-01T16:12:27Z
dc.date.available2007-04-14en_US
dc.date.available2009-06-01T16:12:27Z
dc.date.issued2007-04-14en_US
dc.description19 references.en_US
dc.description.abstractGardasil is the first quadrivalent human papillomavirus (HPV)-types 6, 11, 16, 18 recombinant vaccine approved by the FDA on June 8, 2006. It induces genotype-specific virus-neutralizing antibodies and prevents infection with HPV. Various clinical trials demonstrated a reduction in the incidence of vaccine-type-specific persistent infections and of associated moderate- and high-grade cervical dysplasias and carcinomas in situ after its use. Gardasil is currently approved by FDA for prevention of genital warts, cancers and precancerous conditions of cervix and vulva in 9-26 year old females. Three doses of 0.5 ml of gardasil each at 0, 2 and 6 months are given intramuscularly. It is contraindicated in individuals who are hypersensitive to the active substances or to any of the excipients of the vaccine, patients with bleeding abnormalities or patients on anticoagulant therapy and during pregnancy. However, the vaccine, at an estimated $300-500 per course, is too expensive for many women in developing countries. Moreover, question regarding the longevity of the protection by vaccine is still unsolved. Hence, longer studies are required to establish its real status in cancer prevention.en_US
dc.description.affiliationJ and K Health Services, Jammu, J and K, India. rashmichams@yahoo.comen_US
dc.identifier.citationSharma R, Sharma CL. Quadrivalent human papillomavirus recombinant vaccine: the first vaccine for cervical cancers. Journal of Cancer Research and Therapeutics. 2007 Apr-Jun; 3(2): 92-5en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/111384
dc.language.isoengen_US
dc.source.urihttps://www.cancerjournal.neten_US
dc.subject.meshAdulten_US
dc.subject.meshCancer Vaccines --adverse effectsen_US
dc.subject.meshCarcinoma --drug therapyen_US
dc.subject.meshClinical Trials as Topicen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshPapillomavirus Infections --drug therapyen_US
dc.subject.meshPapillomavirus Vaccines --adverse effectsen_US
dc.subject.meshPrevalenceen_US
dc.subject.meshUterine Cervical Neoplasms --drug therapyen_US
dc.subject.meshVaccines, Synthetic --adverse effectsen_US
dc.titleQuadrivalent human papillomavirus recombinant vaccine: the first vaccine for cervical cancers.en_US
dc.typeJournal Articleen_US
dc.typeReviewen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of Cancer Research and Therapeutics